Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jennifer K. Mooi"'
Autor:
Fiona Chionh, Val Gebski, Sheren J. Al-Obaidi, Jennifer K. Mooi, Maressa A. Bruhn, Chee K. Lee, Anderly C. Chüeh, David S. Williams, Andrew J. Weickhardt, Kate Wilson, Andrew M. Scott, John Simes, Jennifer E. Hardingham, Timothy J. Price, John M. Mariadason, Niall C. Tebbutt
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-14 (2022)
Abstract The phase III MAX clinical trial randomised patients with metastatic colorectal cancer (mCRC) to receive first-line capecitabine chemotherapy alone or in combination with the anti-VEGF-A antibody bevacizumab (± mitomycin C). We utilised thi
Externí odkaz:
https://doaj.org/article/87f820d614bf43b899d6fc21783461db
Autor:
Erik van Dijk, Erik van Werkhoven, Rebecca Asher, Jennifer K. Mooi, David Espinoza, Hendrik F. van Essen, Harm van Tinteren, Nicole C. T. van Grieken, Cornelis J. A. Punt, Niall C. Tebbutt, Bauke Ylstra
Publikováno v:
van Dijk, E, van Werkhoven, E, Asher, R, Mooi, J K, Espinoza, D, van Essen, H F, van Tinteren, H, van Grieken, N C T, Punt, C J A, Tebbutt, N C & Ylstra, B 2022, ' Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer : A post hoc analysis of the randomized phase III-trial AGITG-MAX ', International Journal of Cancer, vol. 151, no. 7, pp. 1166-1174 . https://doi.org/10.1002/ijc.34061
International Journal of Cancer, 151(7), 1166-1174. Wiley-Liss Inc.
International Journal of Cancer, 151(7), 1166-1174. Wiley-Liss Inc.
The VEGF-A monoclonal antibody bevacizumab is currently recommended for first-line treatment of all metastatic colorectal cancer (mCRC) patients. Cost-benefit ratio and side-effects however necessitate patient selection. A large retrospective yet non
Autor:
Ian Y. Luk, Laura J. Jenkins, Kael L. Schoffer, Irvin Ng, Janson W. T. Tse, Dmitri Mouradov, Stanislaw Kaczmarczyk, Rebecca Nightingale, Allan D. Burrows, Robin L. Anderson, Diego Arango, Higinio Dopeso, Larry Croft, Mark F. Richardson, Oliver M. Sieber, Yang Liao, Jennifer K. Mooi, Natalia Vukelic, Camilla M. Reehorst, Shoukat Afshar-Sterle, Vicki L. J. Whitehall, Lochlan Fennell, Helen E. Abud, Niall C. Tebbutt, Wayne A. Phillips, David S. Williams, Wei Shi, Lisa A. Mielke, Matthias Ernst, Amardeep S. Dhillon, Nicholas J. Clemons, John M. Mariadason
Publikováno v:
Scientia
Epigenetics; Tumour-suppressor proteins Epigenética; Proteínas supresoras de tumores Epigenètica; Proteïnes supresores de tumors Colorectal cancers (CRCs) often display histological features indicative of aberrant differentiation but the molecula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c1771def1a2b343893e5c103bb2bd76
Publikováno v:
Contact lensanterior eye : the journal of the British Contact Lens Association. 40(3)
To compare clinical tear film break-up time measurements obtained non-invasively, with those measured following minimal and conventional volumes of fluorescein instillation.Forty-one subjects (20 male, 21 female, mean±SD age 34±11years), with or wi
Publikováno v:
Australian Journal of Rural Health. 20:265-269
Problem: Townsville Cancer Centre provides video-consultation (VC) services to patients in rural/remote regions of North Queensland in order to improve access to specialist cancer care. The experience and responses of indigenous patients using this s
Autor:
Monika Buhrer Skinner, Sabe Sabesan, Joshua Dass, Jennifer K. Mooi, Michael Collins, Zulfiquer Otty, Kandeepan Thuraisingam
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 7:287-292
AIMS: In this retrospective analysis, we describe the efficacy and tolerability of weekly cisplatin 40 mg/m(2) used in concurrent chemoradiation of head and neck cancer at the Townsville Cancer Centre. METHODS: Review of medical records of patients w
Publikováno v:
The Australian journal of rural health. 20(5)
Townsville Cancer Centre provides video-consultation (VC) services to patients in rural/remote regions of North Queensland in order to improve access to specialist cancer care. The experience and responses of indigenous patients using this service ha